Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals
Alternative Names: Elexacaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals; ELX/TEZ/IVA; Ivacaftor/tezacaftor/VX 445; Kaftrio; Tezacaftor/VX-445/ivacaftor; TRIKAFTA; TRIKAFTA®; VX 445/ivacaftor/tezacaftor; VX-445/TEZ/IVA; VX-445/VX-661/VX-770Latest Information Update: 18 Jul 2024
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Amides; Aminophenols; Antifibrotics; Benzodioxoles; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Indoles; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Small molecules; Sulfonamides
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cystic fibrosis
Most Recent Events
- 15 Jul 2024 Registered for Cystic fibrosis (In adolescents, In children, In the elderly, In adults) in Canada (PO)
- 18 Jun 2024 Vertex Pharmaceuticals plans a phase III trial for Cystic-fibrosis (In adolesecents, In adults, In the elderly) (PO, Granules) in October 2024 (NCT06460506) (EudraCT2023-509563-24-00)
- 10 Jun 2024 Adverse events and efficacy data from a phase-III trial in Cystic fibrosis released by Vertex Pharmaceuticals